The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation - PubMed
5 hours ago
- #GLP-1 receptor agonists
- #Obesity pharmacotherapy
- #Incretin therapies
- The article reviews the role of GLP-1 receptor agonists (GLP-1RAs) and multi-agonist incretin therapies in managing specific obesity-related health conditions.
- It provides evidence and rationale for prioritizing these therapies in conditions such as cardiovascular disease, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, obstructive sleep apnea, polycystic ovary syndrome, and others.
- Highlights the applicability of these treatments across a wide range of comorbidities, including asthma, cancer survival, hidradenitis suppurativa, idiopathic intracranial hypertension, osteoarthritis, psoriasis, and subfertility.
- Notes the availability of specific agents like semaglutide, liraglutide, and tirzepatide, and references recent NICE and NHS England guidance on their use for overweight and obesity management.
- Discloses that some authors have received research funding, speaker fees, or advisory fees from pharmaceutical companies such as Novo Nordisk, Eli Lilly, and others, indicating potential conflicts of interest.